Overview
Portfolio
More
Bbv
Berkeley, United States
Backing deep-tech founders tackling fundamental scientific challenges in AI, synthetic biology, energy, and gene therapy.
Portfolio
1+
Employees
3+
Founded
2017
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Bbv
Backing deep-tech founders tackling fundamental scientific challenges in AI, synthetic biology, energy, and gene therapy.
Portfolio
1+
Employees
3+
Founded
2017
AUM
N/A
Stages
No stages listed
Industries
No industries listedGeographic scope
United States
Sources
Showing 1 of 1 matched portfolio company
GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.
Funding: $24.0M
Rough estimate of the amount of funding raised
Funding: $24.0M
Rough estimate of the amount of funding raised